Oridonin is a natural product derived from the Rabdosia rubescens plant. It has gained attention for its anti-cancer properties and potential therapeutic benefits in a variety of cancers. Oridonin targets several signaling pathways involved in cancer cell survival and proliferation, making it a promising candidate for cancer therapy.
Chemical name:
(1R,2R,4aS,5aR,6S,8aR,9R,10aS,12aR)-6-Hydroxy-1,1,4a,5a,6,9,10,10a-octamethyl-3,9-(epoxymethano)oxireno[6',5',6':13,14]-cyclodeca[1,2-b]furan-2,11-dione
Molecular formula:
C20H28O6
Formula weight:
364.44 g/mol
CAS No:
28957-04-2
Top ten keywords from Google and synonyms:
Health benefits of this product:
Oridonin has shown potential health benefits in the treatment of various types of cancer, including breast, lung, ovarian, and pancreatic cancers. Studies have shown that oridonin can induce apoptosis, or programmed cell death, in cancer cells, thereby preventing tumor growth and metastasis. Additionally, oridonin has been found to inhibit the activation of several signaling pathways that contribute to tumorigenesis, making it a promising candidate for cancer therapy.
Potential effects:
Oridonin has several potential effects on cancer cells. One of the primary mechanisms is through the induction of apoptosis, which occurs through the activation of caspases and the disruption of mitochondrial function. Oridonin has also been found to inhibit the activation of several signaling pathways involved in cancer cell survival and proliferation, including NF-κB and AKT. Additionally, oridonin has been found to have anti-metastatic effects, inhibiting the migration and invasion of cancer cells.
Product mechanism:
Oridonin works by targeting several signaling pathways involved in cancer cell survival and proliferation. One of the primary mechanisms is through the induction of apoptosis, which occurs through the activation of caspases and the disruption of mitochondrial function. Oridonin has also been found to inhibit the activation of several signaling pathways involved in cancer cell survival and proliferation, including NF-κB and AKT. Additionally, oridonin has been found to have anti-metastatic effects, inhibiting the migration and invasion of cancer cells.
Safety:
Oridonin has been found to be generally safe in preclinical studies. However, further research is needed to determine the safety and efficacy of oridonin in humans.
Side effects:
Currently, there is limited information available regarding the potential side effects of oridonin. Some studies have suggested that high concentrations of oridonin may cause liver injury and gastrointestinal disturbances. Further research is needed to determine the full extent of the drug's side effects.
Dosing information:
There are currently no established guidelines for the dosing of oridonin in humans. Doses used in preclinical studies have ranged from 0.3 to 20 mg/kg. Further research is needed to determine the optimal dosing regimen for oridonin in humans.
Conclusion:
Oridonin is a promising candidate for cancer therapy due to its ability to target several signaling pathways involved in cancer cell survival and proliferation. The drug has been shown to induce apoptotic cell death and prevent tumor growth and metastasis in several types of cancer cells. However, its safety and efficacy in humans need to be further studied. Overall, oridonin shows great promise as a targeted therapy for cancer, and may provide valuable insights into the development of future treatments for various types of cancer
